natgillin/translations-raw huggingface dataset:
This includes any possible side effects not listed in this leaflet. 
Seznam neželenih učinkov v preglednici
EXPIRY DATE 
Datumprveodobritve:
The safety of posaconazole oral suspension has been assessed in > 2,400 patients and healthy volunteers enrolled in clinical trials and from post-marketing experience. 
Povzetek varnostnega profila Varnost peroralnesuspenzije posakonazola soocenilipri> 2.400 bolnikih in zdravih prostovoljcih,vključenih v klinična preskušanja, in na podlagi izkušenj med obdobjemtrženja.Mednajpogostejeporočanimi resnimi, z zdravilom povezanimi neželenimi učinki so bili navzea, bruhanje, driska,zvišana telesna temperatura in zvišanaraven bilirubina.
Gastrointestinal dysfunction 
Bolezni mišično-skeletnega sistemain vezivnega tkiva
nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %, respectively. 
Pri uporabiponavljajočihse odmerkovfosamprenavirja (700 mgdvakratnadan 10dni) sta se Cmaxin AUC posakonazola v oblikiperoralne suspenzije (200 mg enkratna dan prvidan, 200 mg dvakrat na dan drugi dan, nato 400 mgdvakratnadan 8dni) zmanjšaliza 21 %oz.
The primary efficacy endpoint was the incidence of proven/probable IFIs at 16 weeks post-randomization as determined by an independent, blinded external expert panel. 
Primarni opazovani dogodekučinkovitostijebila pojavnostdokazanihoziroma verjetnih invazivnih glivnih okužb 16 tednov po randomizaciji,
Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). 
Sočasna uporaba azolskih antimikotikov, vključno s posakonazolom, in vinkristina je bila povezana zresnimineželenimi učinki (glejte poglavje 4.4).Posakonazollahko zviša plazemsko koncentracijo alkaloidovvinkekarlahkovodidonevrotoksičnostiindrugihresnihneželenihučinkov.
Since certain adverse reactions (e.g. dizziness, somnolence, etc.) have been reported with posaconazole use, which potentially may affect driving/operating machinery, caution needs to be used. 
itd.), ki lahko poslabšajo sposobnost vožnje in upravljanja s stroji, je potrebna previdnost.
What Posaconazole AHCL contains 
Posakonazol AHCL.
In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days) increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83 %. 
povečala izpostavljenost (AUC) intravensko uporabljenemu midazolamu (0,05 mg/kg)za
Vinca alkaloids 
Middlesex
Posaconazole AHCL can increase the amount of these medicines in the blood which may lead to very serious changes to your heart rhythm: - any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine used to treat migraines. 
Zdravilo Posakonazol AHCL vsebuje učinkovino posakonazol.Taučinkovinaspada v skupinozdravil,imenovanih"antimikotiki"(protiglivna zdravila).
Possible side effects 
Drugi neželeni učinki
The excreted metabolites in urine and faeces account for approximately 17 % of the administered radiolabelled dose. 
17%uporabljenegaradioaktivno označenega odmerka.
Alternatively, if recommended by your doctor, you may take 400 mg (two 5 mL spoonfuls) twice a day provided that you are able to take both doses during or after food or a nutritional drink. 
čeimate možnost, data dva odmerka vzamete medali takojpojediali zaužitju prehranskega dopolnila v obliki napitka.
Packaging Package size 
Način uporabe Pakiranje Velikost pakiranja
It can also be given with an infusion pump. 
Daje se lahko tudi z infuzijsko črpalko.
This means that it is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU). 
To pomeni, da je zelo podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
The doctor should instruct the patient on how to use the medicine properly. 
Zdravnik mora bolnika poučiti o pravilni uporabi zdravila.
Severe hypoglycaemia can lead to loss of consciousness and, in very extreme cases, to death. 
Huda hipoglikemija lahko privede do izgube zavesti in v skrajnih primerih do smrti.
Hypoglycaemia may be due to the medicine itself or other factors such as diet and exercise. 
Hipoglikemija je lahko posledica samega zdravila ali pa drugih dejavnikov, kot sta prehrana in vadba.
In some circumstances, such as when blood acid levels are dangerously high (ketoacidosis), the medicine may be given into a vein. 
V nekaterih okoliščinah, na primer, kadar so ravni kisline v krvi nevarno visoke (ketoacidoza), se lahko daje v veno.
In addition, studies have shown that both medicines produce similar levels of the active substance in the body. 
Poleg tega so študije pokazale, da obe zdravili proizvedeta podobno količino zdravilne učinkovine v telesu.
It helps control blood glucose levels, thereby alleviating symptoms and reducing the risk of complications of diabetes. 
Pripomore k nadzoru ravni glukoze v krvi in s tem olajša simptome ter zmanjša tveganje za zaplete sladkorne bolezni.
In diabetes, patients have high levels of blood glucose either because the body does not produce enough insulin or the body is unable to use insulin effectively. 
Pri sladkorni bolezni imajo bolniki visoko raven glukoze v krvi, ker telo ne proizvaja dovolj insulina ali pa ga ne more učinkovito izrabiti.
The full EPAR for Insulin lispro Sanofi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Insulin lispro Sanofi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In addition, studies show that both medicines have similar effects in reducing blood glucose levels and similar side effects. 
Poleg tega so študije pokazale, da imata obe zdravili podoben učinek na zniževanje ravni glukoze v krvi in podobne neželene učinke.
In one study, in patients with type 1 diabetes, HbA1c reduced by 0.44 and 0.46 percentage points with Insulin lispro Sanofi and Humalog respectively after 26 weeks; in the second study, in patients with type 2 diabetes, the corresponding figures were 0.93 versus 0.88 percentage points. 
V eni študiji pri bolnikih s sladkorno boleznijo tipa 1 se je vrednost HbA1c po 26 tednih znižala za 0,44 odstotne točke z zdravilom Insulin lispro Sanofi in za 0,46 odstotne točke z zdravilom Humalog, v drugi študiji pri bolnikih s sladkorno boleznijo tipa 2 pa sta bili vrednosti 0,93 oziroma 0,88 odstotne točke.
The active substance in Insulin lispro Sanofi is a form of insulin which is absorbed more quickly by the body than human regular insulin, and can therefore act faster. 
Zdravilna učinkovina v zdravilu Insulin lispro Sanofi je oblika insulina, ki ga telo absorbira hitreje kot običajni humani insulin, zato lahko deluje hitreje.
This is a summary of the European public assessment report (EPAR) for Insulin lispro Sanofi. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Insulin lispro Sanofi.
Because Insulin lispro Sanofi is a fast-acting insulin, it is usually given shortly before a meal and, when necessary, soon after a meal. 
Ker je zdravilo Insulin lispro Sanofi hitrodelujoči insulin, se običajno daje tik pred obrokom in po potrebi kmalu po obroku.
Insulin lispro Sanofi may cause hypoglycaemia (low blood glucose levels) and must not be given to patients whose blood glucose is already low. 
Zdravilo Insulin lispro Sanofi lahko povzroča hipoglikemijo (nizke ravni glukoze v krvi) in se ne sme dajati bolnikom, ki že imajo nizke ravni glukoze v krvi.
For more information about treatment with Insulin lispro Sanofi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Insulin lispro Sanofi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What measures are being taken to ensure the safe and effective use of Insulin lispro Sanofi? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Insulin lispro Sanofi?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements for biosimilar medicines, Insulin lispro Sanofi has a highly similar structure, purity and biological activity to Humalog and is distributed in the body in the same way. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Insulin lispro Sanofi po zgradbi, čistosti in biološkem delovanju zelo podobno zdravilu Humalog in da se po telesu enako porazdeli.
Insulin lispro Sanofi is a medicine used to control blood glucose (sugar) levels in adults and children with diabetes who need insulin. 
Zdravilo Insulin lispro Sanofi se uporablja za uravnavanje ravni glukoze (sladkorja) v krvi pri odraslih in otrocih s sladkorno boleznijo, ki potrebujejo insulin.
Therefore, the CHMP's view was that, as for Humalog, the benefits of Insulin lispro Sanofi outweigh its risks and recommended that it be given marketing authorisation. 
Zato je odbor CHMP menil, da koristi zdravila Insulin lispro Sanofi enako kot pri zdravilu Humalog odtehtajo z njim povezana tveganja, in priporočil, da se zanj izda dovoljenje za promet.
The dose of Insulin lispro Sanofi is worked out for each patient and depends on the patient's blood glucose level. 
Odmerek zdravila Insulin lispro Sanofi se prilagodi posameznemu bolniku in je odvisen od bolnikove ravni glukoze v krvi.
For practical information about using Insulin lispro Sanofi, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Insulin lispro Sanofi naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Insulin lispro Sanofi, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Insulin lispro Sanofi glejte navodilo za uporabo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Insulin lispro Sanofi have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Insulin lispro Sanofi upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The reference medicine for Insulin lispro Sanofi is Humalog 100 U/ml solution. 
Referenčno zdravilo za zdravilo Insulin lispro Sanofi je zdravilo Humalog 100 e./ml raztopina.
Laboratory studies comparing Insulin lispro Sanofi with the reference medicine Humalog have shown that the active substance in Insulin lispro Sanofi is highly similar in terms of structure, purity and biological activity to that of Humalog. 
Laboratorijske študije, v katerih so zdravilo Insulin lispro Sanofi primerjali z referenčnim zdravilom Humalog, so pokazale, da je zdravilna učinkovina v zdravilu Insulin lispro Sanofi po zgradbi, čistosti in biološkem delovanju zelo podobna zdravilni učinkovini v zdravilu Humalog.
Two further studies in a total of 1,012 patients compared Insulin lispro Sanofi with Humalog and found them to be similarly effective at reducing blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose levels are controlled over time. 
Dve nadaljnji študiji pri skupaj 1 012 bolnikih sta primerjali zdravilo Insulin lispro Sanofi z zdravilom Humalog in ugotovili, da sta podobno učinkoviti pri zniževanju ravni snovi v krvi, imenovane glikirani hemoglobin (HbA1c).
Insulin lispro Sanofi is a ‘biosimilar medicine'. 
Zdravilo Insulin lispro Sanofi je „podobno biološko zdravilo“.
Insulin lispro Sanofi is given as an injection under the skin in the upper arm, thigh, buttock or belly. 
Zdravilo Insulin lispro Sanofi se injicira v podkožje, in sicer v nadlaket, stegno, zadnjico ali trebuh.
What is Insulin lispro Sanofi and what is it used for? 
Kaj je zdravilo Insulin lispro Sanofi in za kaj se uporablja?
Other information about Insulin lispro Sanofi 
Druge informacije o zdravilu Insulin lispro Sanofi
What are the risks associated with Insulin lispro Sanofi? 
Kakšna tveganja so povezana z zdravilom Insulin lispro Sanofi?
It contains the active substance insulin lispro. 
Vsebuje zdravilno učinkovino insulin lispro.
What benefits of Insulin lispro Sanofi have been shown in studies? 
Kakšne koristi je zdravilo Insulin lispro Sanofi izkazalo v študijah?
Why is Insulin lispro Sanofi approved? 
Zakaj je bilo zdravilo Insulin lispro Sanofi odobreno?
How does Insulin lispro Sanofi work? 
Kako zdravilo Insulin lispro Sanofi deluje?
How is Insulin lispro Sanofi used? 
Kako se zdravilo Insulin lispro Sanofi uporablja?
The European Commission issued a decision on 28 September 2012. 
Evropska komisija je odločbo izdala dne 28. septembra 2012.
France, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom). 
Luksemburg, Malta, Norveška, Poljska, Portugalska, Romunija, Slovaška, Slovenija, Španija, Švedska in Združeno kraljestvo).
Why was Yvidually reviewed? 
Zakaj je bilo zdravilo Yvidually pregledano?
However, the Member States were not able to reach an agreement and the Netherlands referred the matter to the CHMP for arbitration on 23 February 2012. 
Vendar pa države članice niso uspele doseči soglasja, zato je Nizozemska 23. februarja 2012 zadevo napotila na CHMP v arbitražo.
This is a procedure where one Member State (the ‘reference Member State', in this instance the Netherlands) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Finland, 
To je postopek, v katerem ena od držav članic („referenčna država članica“, v tem primeru Nizozemska) oceni zdravilo z namenom odobritve dovoljenja za promet z zdravilom, ki bo veljavno v tej državi in drugih državah članicah („zadevne države članice“, v tem primeru Avstrija, Belgija, Bolgarija, Ciper, Češka republika, Danska, Estonija, Nemčija, Grčija, Finska, Francija, Madžarska, Islandija, Irska, Italija, Latvija, Litva,
France was also concerned that the tablet dispenser had not been used in the main clinical studies. 
Francija je imela pomisleke tudi glede tega, da delilnik tablet ni bil uporabljen v glavnih kliničnih študijah.
Yvidually is a combined contraceptive pill. 
Zdravilo Yvidually je kombinirana kontracepcijska tableta.
On 19 April 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Yvidually and associated names. 
Evropska agencija za zdravila je 19. aprila 2012 zaključila postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Yvidually in povezanih imen.
Yvidually is an ‘extended use' oral contraceptive, which means that it can be taken daily for up to 120 days. 
Zdravilo Yvidually je peroralno kontracepcijsko sredstvo s „podaljšano uporabo“, kar pomeni, da se lahko jemlje vsak dan do 120 dni skupaj.
Based on evaluation of the available data and the scientific discussion within the Committee, the CHMP concluded that the contraceptive effectiveness during an extended use had been demonstrated. 
CHMP je na podlagi ocene razpoložljivih podatkov in znanstvene razprave v Odboru zaključil, da je bila učinkovitost kontracepcijskega sredstva med podaljšano uporabo dokazana.
It contains two active substances, ethinylestradiol and drospirenone, which are derived from natural hormones produced in the ovaries: ethinylestradiol is derived from oestrogen and drospirenone is derived from progesterone. 
Vsebuje dve zdravilni učinkovini, etinilestradiol in drospirenon, pridobljeni iz naravnih hormonov, ki se tvorita v jajčnikih: etinilestradiol se pridobiva iz estrogena, drospirenon pa iz progesterona.
While different bleeding patterns had been reported during the days of pill intake, these bleeding episodes seemed to be well tolerated. 
Čeprav so ženske poročale o različnih vzorcih krvavitev v dneh jemanja tablet, se zdi, da so te krvavitve dobro prenašale.
What is Yvidually? 
Kaj je zdravilo Yvidually?
The grounds for the referral were concerns by France about the effectiveness of the proposed extended use of the medicine and the irregular bleeding episodes that might occur during the days of intake of the pill. 
Razlog za napotitev so bili pomisleki Francije o učinkovitosti predlagane podaljšane uporabe zdravila in neredne krvavitve, do katerih lahko pride med obdobjem jemanja tablet.
This medicine will be marketed also as Flexyess. 
To zdravilo se bo tržilo tudi pod imenom Flexyess.
Yvidually works by changing the body's hormonal balance to prevent ovulation, by altering the mucus in the cervix (neck of the womb) and by thinning the endometrium (the lining of the womb). 
Zdravilo Yvidually deluje tako, da spremeni hormonsko ravnovesje telesa in s tem prepreči ovulacijo, povzroči spremembo sluzi v cerviksu (materničnem vratu) ter tanjša endometrij (maternično sluznico).
The CHMP also noted that the concerns over the tablet dispenser had been adequately addressed, as an additional study provided by the company showed that women find the dispenser easy to use and that there were no problems with posology compliance. 
CHMP je ugotovil tudi, da so bili pomisleki glede delilnika tablet ustrezno obravnavani, saj je dodatna študija, ki jo je izvedla družba, pokazala, da so ženske delilnik ocenile kot enostaven za uporabo in da ni bilo nobenih težav s pravilnim odmerjanjem.
The option of a tablet-free interval at any time during day 25 to 120 of the treatment cycle is also allowed. 
Prav tako je možno za določeno obdobje prekiniti jemanje tablet, in sicer kadar koli med 25. in 120. dnevom ciklusa jemanja.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Yvidually outweigh its risks, and the marketing authorisation can be granted in all EU Member States as well as Iceland and Norway. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi zdravila Yvidually odtehtajo njegova tveganja in da se lahko odobri dovoljenje za promet v vseh državah članicah EU ter v Islandiji in na Norveškem.
Yvidually will be available as tablets in an automated tablet dispenser device with a reminder function for when the next pill has to be taken. 
Zdravilo Yvidually bo na voljo v obliki tablet, shranjenih v avtomatskem delilniku tablet, ki uporabnika opomni, da je čas za naslednji odmerek.
The CHMP therefore concluded that the benefits of Yvidually outweigh its risks, and therefore the marketing authorisation for Yvidually should be granted in all concerned Member States. 
CHMP je tako zaključil, da so koristi zdravila Yvidually večje od z njim povezanih tveganj, in priporočil, da se dovoljenje za promet z zdravilom Yvidually odobri v vseh zadevnih državah članicah.
Bayer B.V. submitted Yvidually to the Netherlands medicines regulatory agency for a decentralised procedure. 
je nizozemski regulatorni agenciji za zdravila predložila vlogo za pridobitev dovoljenja za promet z zdravilom Yvidually po decentraliziranem postopku.
The European Commission granted a marketing authorisation valid throughout the European Union for Glidipion on 15 March 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Glidipion, veljavno po vsej Evropski uniji, odobrila dne 15. marca 2012.
The full EPAR for Glidipion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Glidipion je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This means that Glidipion is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
Treatment with Glidipion should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. 
Zdravljenje z zdravilom Glidipion je treba ponovno oceniti po treh do šest mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, ukiniti.
For more information about treatment with Glidipion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Glidipion preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Glidipion. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Glidipion.
The active substance in Glidipion, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. 
Zdravilna učinkovina zdravila Glidipion, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glidipion. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Glidipion, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Glidipion 
Druge informacije o zdravilu Glidipion
Because Glidipion is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Glidipion generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Glidipion is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight. 
Zdravilo Glidipion se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
The Committee recommended that Glidipion be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Glidipion odobri dovoljenje za promet.
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed. 
Priporočeni začetni odmerek zdravila Glidipion je 15 ali 30 mg enkrat na dan. Odmerek bo po enem ali dveh tednih morda treba povečati do 45 mg enkrat na dan, če je potreben boljši nadzor glukoze (sladkorja) v krvi.
The CHMP concluded that, in accordance with EU requirements, Glidipion has been shown to have comparable quality and to be bioequivalent to Actos. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Glidipion primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
Glidipion is a ‘generic medicine'. 
Zdravilo Glidipion je „generično zdravilo“.
Glidipion is a medicine that contains the active substance pioglitazone. 
Glidipion je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
Because Glidipion is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos. 
Ker je zdravilo Glidipion generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
What is the risk associated with Glidipion? 
Kakšna tveganja so povezana z zdravilom Glidipion?